Briefing
Postoperative adjuvant therapy for cervical cancer based on minimal residual disease
Phase 2 trial that assigns adjuvant treatment from risk group and MRD status. The registry primary outcome is 3-year disease-free survival. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting